1. Home
  2. CXAI vs CRIS Comparison

CXAI vs CRIS Comparison

Compare CXAI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.37

Market Cap

17.8M

Sector

Technology

ML Signal

HOLD

Logo Curis Inc.

CRIS

Curis Inc.

HOLD

Current Price

$1.05

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXAI
CRIS
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
14.6M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CXAI
CRIS
Price
$0.37
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.50
AVG Volume (30 Days)
2.8M
118.2K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,222,000.00
$11,650,000.00
Revenue This Year
N/A
$6.13
Revenue Next Year
$70.21
$8.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.56
52 Week Low
$0.36
$1.02
52 Week High
$2.54
$4.50

Technical Indicators

Market Signals
Indicator
CXAI
CRIS
Relative Strength Index (RSI) 38.42 33.58
Support Level $0.37 $1.14
Resistance Level $0.41 $1.41
Average True Range (ATR) 0.06 0.09
MACD 0.00 -0.02
Stochastic Oscillator 3.29 1.28

Price Performance

Historical Comparison
CXAI
CRIS

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Share on Social Networks: